基于微流控实时PCR的成人弥漫性胶质瘤术中快速基因分型
本研究开发基于GeneSoC微流控实时PCR平台的快速基因分型系统,可在20分钟内完成50个PCR循环。利用67例冷冻肿瘤组织和人工DNA载体确定最佳分析条件,对IDH1 R132H和TERT启动子C228T/C250T突变的检测下限至少为5%变异等位基因频率。在120例术中检测中,IDH1 R132H突变灵敏度和特异度分别为0.985和0.982,TERT启动子C228T/C250T突变均为1.000,突变可在组织采集后约25分钟内术中检出。
要点
- GeneSoC系统可在20分钟内完成50个PCR循环,术中约25分钟检出IDH1和TERT启动子突变。
- IDH1 R132H突变检测灵敏度0.985、特异度0.982;TERT启动子C228T/C250T突变灵敏度和特异度均为1.000。
- 该系统还可用于识别IDH突变胶质瘤的肿瘤边界。
核心结论
- 基于GeneSoC的快速基因分型系统可能不仅有效用于弥漫性胶质瘤的术中诊断,还可用于检测肿瘤边界。
研究设计与样本
- 研究使用GeneSoC实时PCR平台,该平台具有微流控热循环能力,可在20分钟内完成50个PCR循环。
- 采用67例患者的冷冻肿瘤组织和人工DNA载体分析以建立最佳分析条件。
- 随后在120例病例中使用该系统进行术中检测。
主要发现
- 该系统对IDH1 R132H和TERT启动子C228T/C250T突变的检测下限至少为5%变异等位基因频率。
- IDH1 R132H突变的灵敏度和特异度分别为0.985和0.982。
- TERT启动子C228T/C250T突变的灵敏度和特异度分别为1.000和1.000。
- 这些突变在肿瘤组织采集后约25分钟内于术中检出。
- 该检测在一例IDH突变胶质瘤中识别出肿瘤边界,而该区域未能检测到IDH1 R132H突变。
临床怎么用
- 该快速基因分型系统可在术中约25分钟内提供IDH1 R132H和TERT启动子突变状态,辅助弥漫性胶质瘤的术中诊断。
- 该系统还可用于检测IDH突变胶质瘤的肿瘤边界。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The 5th edition of the World Health Organization Classification of Tumors of the CNS introduced a subclassification of tumors based on key molecular markers. In adult-type diffuse gliomas, isocitrate dehydrogenase (IDH) and telomerase reverse transcriptase (TERT) promoter mutations play pivotal roles in the molecular classification. This study developed a rapid genotyping system using GeneSoC, a real-time PCR platform with microfluidic thermal cycling capable of completing 50 cycles of PCR within 20 min. METHODS: To establish optimal analytical conditions, frozen tumor tissues from 67 patients and artificial DNA vectors were analyzed using this system. This system demonstrated a detection limit of at least 5% variant allele frequency for the IDH1 R132H and TERT promoter C228T/C250T mutations. Subsequently, intraoperative testing was performed in 120 cases using this system. RESULTS: The sensitivity and specificity of IDH1 R132H mutation were 0.985 and 0.982, respectively, whereas those of TERT promoter C228T/C250T mutation were 1.000 and 1.000, respectively. These mutations were detected intraoperatively within approximately 25 min after tumor tissue collection. Furthermore, this assay identified tumor boundaries in an IDH-mutated glioma case, where IDH1 R132H mutations could not be detected. CONCLUSIONS: The GeneSoC®︎-based rapid genotyping system may be effective not only for intraoperative diagnosis of diffuse glioma but also for detecting tumor boundaries.
引用
- Maeda S, Kitano Y, Ohka F, et al. Rapid intraoperative genetic analysis of adult-type diffuse gliomas using a microfluidic real-time polymerase chain reaction device. Neuro Oncol. 2025. PMID: 40851364. doi:10.1093/neuonc/noaf188
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。